Valuation : StemRIM

Market Cap 18.68B 122M 105M 99.28M 89.9M 169M 11.61B 170M 1.17B 452M 5.94B 457M 447M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 11.68B 76.17M 65.59M 62.11M 56.24M 105M 7.26B 106M 731M 283M 3.71B 286M 279M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.06%
Yield 2024 *
-
Yield 2025 -
1 day-24.69%
1 week-42.31%
Current month-45.78%
1 month-44.79%
3 months-36.40%
6 months-40.79%
Current year-31.56%
1 week 177
Extreme 177
337
1 month 177
Extreme 177
368
Current year 177
Extreme 177
368
1 year 177
Extreme 177
368
3 years 177
Extreme 177
830
5 years 177
Extreme 177
1,518
10 years 177
Extreme 177
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 30/09/2022
Chief Executive Officer 58 24/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 31/01/2007
Director/Board Member 58 28/02/2019
Director/Board Member 54 30/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-24.69%-42.31%-41.75%-77.75% 73.46M
-1.48%-5.59%+37.54%-6.24% 78.02B
-1.42%-4.24%-18.81%-37.78% 57.4B
+5.38%-1.09%+467.03%+36.08% 57.48B
-0.56%-2.21%-11.17%+25.38% 48.81B
+1.93%-2.37%-2.00%+149.45% 45.5B
+0.80%-1.67%+45.89%-16.13% 32.08B
-1.47%-4.17%+40.97%+88.59% 24.62B
-0.85%-8.64%-3.66%+144.26% 20.77B
-0.09%-3.61%+63.58%+97.66% 15.75B
Average -2.24%-7.72%+57.76%+40.35% 38.05B
Weighted average by Cap. +0.37%-3.72%+82.68%+35.87%

Financials

2024 2025
Net sales - -
Net income -2.02B -13.18M -11.35M -10.75M -9.73M -18.25M -1.26B -18.36M -127M -48.95M -642M -49.45M -48.36M -1.93B -12.58M -10.83M -10.25M -9.28M -17.41M -1.2B -17.52M -121M -46.7M -613M -47.18M -46.14M
Net Debt -8.41B -54.82M -47.21M -44.7M -40.48M -75.92M -5.23B -76.37M -526M -204M -2.67B -206M -201M -6.99B -45.59M -39.26M -37.17M -33.66M -63.13M -4.35B -63.51M -438M -169M -2.22B -171M -167M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
11/09/26 JP¥180.00 -24.69% 5,303,600
10/09/26 JP¥239.00 -25.08% 136,500
09/09/26 JP¥319.00 -3.33% 265,300
08/09/26 JP¥330.00 -0.30% 325,000
07/09/26 JP¥331.00 +6.09% 283,300
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!